Table 3.

Randomized Trials of Selective Estrogen Receptor Modulators to Prevent Bone Loss During Gonadotropin-Releasing Hormone Agonist Therapy

Study	n	Treatment	Outcomes
Smith et al33	48	Raloxifene vs	Increased BMD of the
		no raloxifene	hip and spine
Steiner et al34	46	Toremifene vs	Increased BMD
		placebo	Reduced hot flashes

BMD, bone mineral density.